Analytical Data
-
基因名
CD7
- Application
-
别名
CD7；T-cell antigen CD7
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P09564
-
表达区间
1-180aa
-
氨基酸序列
MAGPPRLLLL PLLLALARGL PGALAAQEVQ QSPHCTTVPV GASVNITCST SGGLRGIYLR QLGPQPQDII YYEDGVVPTT DRRFRGRIDF SGSQDNLTIT MHRLQLSDTG TYTCQAITEV NVYGSGTLVL VTEEQSQGWH RCSDAPPRAS ALPAPPTGSA LPDPQTASAL PDPPAASALP
-
分子量
18 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD7 is a glycoprotein that plays a crucial role in T-cell development and function, primarily expressed on T cells and natural killer (NK) cells. Its involvement in immune responses has drawn considerable attention in immunology and cancer research. Studies have shown that CD7 can act as a co-stimulatory molecule, contributing to T-cell activation and proliferation. Abnormal expression of CD7 has been implicated in various hematological malignancies, including T-cell leukemia. This has led to increased interest in CD7 as a potential therapeutic target for immunotherapeutic approaches. Recombinant CD7 proteins have been developed to explore their potential in enhancing immune responses, as well as to serve as targets for bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies. Understanding the structure and function of CD7 through recombinant protein studies can provide critical insights into its role in T-cell biology and pave the way for novel therapeutic strategies targeting CD7 in cancer and immune disorders. The research surrounding recombinant CD7 proteins has significant implications for advancing cancer immunotherapy and improving patient outcomes.
